PPARG and familial pancreatic carcinoma: Furthermore, the first-line drug for the treatment of unresectable pancreatic cancer is represented by the nucleoside analog gemcitabine, and PPARγ ligands potentiate its cytotoxic action on human pancreatic cancer cells in a dosage-dependent manner and are tested to improve the prognosis of pancreatic cancer patients [42].